Mutual of America Capital Management LLC Reduces Stake in Zoetis Inc. (NYSE:ZTS)

Mutual of America Capital Management LLC reduced its position in Zoetis Inc. (NYSE:ZTS) by 4.4% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 57,671 shares of the company’s stock after selling 2,662 shares during the period. Mutual of America Capital Management LLC’s holdings in Zoetis were worth $9,998,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Webster Bank N. A. raised its holdings in Zoetis by 89.1% during the first quarter. Webster Bank N. A. now owns 174 shares of the company’s stock valued at $29,000 after acquiring an additional 82 shares during the period. Neo Ivy Capital Management bought a new stake in Zoetis during the fourth quarter worth approximately $40,000. LRI Investments LLC bought a new position in shares of Zoetis during the first quarter valued at approximately $43,000. Ables Iannone Moore & Associates Inc. bought a new position in shares of Zoetis during the fourth quarter valued at approximately $51,000. Finally, Hazlett Burt & Watson Inc. grew its stake in shares of Zoetis by 60.7% during the first quarter. Hazlett Burt & Watson Inc. now owns 270 shares of the company’s stock valued at $46,000 after buying an additional 102 shares during the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Price Performance

NYSE:ZTS opened at $196.48 on Thursday. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. The stock has a market capitalization of $89.65 billion, a PE ratio of 37.86, a price-to-earnings-growth ratio of 2.98 and a beta of 0.88. The stock’s 50-day moving average price is $184.11 and its 200-day moving average price is $174.31.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The firm had revenue of $2.36 billion for the quarter, compared to analysts’ expectations of $2.31 billion. During the same period last year, the firm earned $1.41 EPS. The company’s quarterly revenue was up 8.3% on a year-over-year basis. As a group, equities analysts expect that Zoetis Inc. will post 5.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ZTS has been the topic of several research analyst reports. Argus raised Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Stifel Nicolaus raised their target price on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday. Piper Sandler raised their target price on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Finally, BTIG Research lifted their price objective on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $218.22.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.